Drug Development.

Area of Science:

• Neuroscience
• Biochemistry
• Pharmacology

Background:

• Alzheimer's disease (AD) treatments are limited, necessitating novel therapeutic strategies targeting biochemical pathways.
• Metabolic disruptions and neuroinflammation are key factors in cognitive decline.
• Phytochemicals like resveratrol are being investigated for their potential to modify AD progression.

Purpose of the Study:

• To investigate the therapeutic potential of resveratrol in alleviating amyloid-beta-induced cellular dysfunction in an Alzheimer's disease model.
• To assess resveratrol's effects on cell viability, oxidative stress, and mitochondrial function.

Main Methods:

• Utilized the BE(2)-M17 neuroblastoma cell line differentiated into mature neurons.
• Treated cells with amyloid-beta (Aβ) after pre-treatment with varying concentrations of resveratrol.
• Assessed cell viability (CellTiter-Glo), oxidative stress (ROS assay), and mitochondrial function (MTT assay).

Main Results:

• 10 µM resveratrol significantly enhanced ATP production and cell viability under Aβ exposure (p = 0.0386).
• 10 µM resveratrol markedly reduced Aβ-induced oxidative stress (p = 0.049).
• 10 µM resveratrol mitigated Aβ-induced mitochondrial dysfunction (p = 0.013).

Conclusions:

• Resveratrol at 10 µM demonstrated significant neuroprotective effects by improving cellular energy, reducing oxidative stress, and preserving mitochondrial integrity.
• These findings highlight resveratrol's potential as a therapeutic agent for Alzheimer's disease by modulating cellular homeostasis and energy metabolism.